Adaptive Biotechnologies (ADPT) Current Leases (2020 - 2026)

Adaptive Biotechnologies has disclosed Current Leases across 7 years of filings, most recently posting $8.8 million for Q2 2026.

• In Q2 2026, Current Leases fell 11.39% year-over-year to $8.8 million; the TTM figure through Jun 2026 stood at $8.8 million (down 11.39% YoY), while the FY2025 annual figure was $8.9 million, down 12.88% from the prior year.
• Current Leases came in at $8.8 million for Q2 2026 at Adaptive Biotechnologies, up from $8.5 million in the prior quarter.
• In the past five years, Current Leases ranged from a high of $10.5 million in Q1 2025 to a low of $8.5 million in Q1 2026.
• Average Current Leases over 5 years is $9.3 million, with a median of $9.4 million recorded in 2023.
• Year-over-year, Current Leases jumped 98.35% in 2022 and declined 18.63% in 2026.
• Over 5 years, Current Leases stood at $9.2 million in 2022, then rose by 1.67% to $9.4 million in 2023, then grew by 9.11% to $10.2 million in 2024, then retreated by 12.88% to $8.9 million in 2025, then dropped by 1.09% to $8.8 million in 2026.
• Per Business Quant data, the three most recent Current Leases figures were $8.8 million in Q2 2026, $8.5 million in Q1 2026, and $8.9 million in Q4 2025.